PM01183: A promising new drug for ovarian cancer

In platinum resistant/ refractory ovarian cancer PM01183 (lurbinectedin) produced an overall response rate of 27%, reported the results of a phase 2 trial presented in the proffered papers session for gynecological cancers at ESMO 2012 in Vienna. PM01183 is a new synthetic entity belonging to the tetrahydroisoquinoline family, which binds to the DNA minor groove inducing DNA breaks and transcription blockage. Read more here.